Table 1 Baseline characteristics of patients with or without 12 months follow-up
Total patients (n = 3849) | Without 12 month follow-up (n = 767) | With 12 month follow-up(n = 3 082) | p-value w vs. w/o follow-up | AZL-M (n = 2 809) | ACE-inhibitor (n = 1 040) | p-valueAZL-M vs. ACE-inhibitor | |
|---|---|---|---|---|---|---|---|
Age, years | 59.4 ± 13,0 | 58.8 ± 13.4 | 59.6 ± 12.9 | 0.29 | 60.1 ± 12.6 | 57.7 ± 13.9 | <0.0001 |
Female, % | 46.8 | 41.5 | 48.1 | <0.001 | 47.9 | 43.8 | <0.05 |
Body weight, kg | 83.3 ± 15.6 | 84.5 ± 15.8 | 83.0 ± 15.6 | <0.05 | 83.4 ± 15.8 | 83.1 ± 15.2 | 0.94 |
Hypertension | |||||||
Newly diagnosed, % | 36.9 | 34.7 | 37.4 | 0.16 | 34.2 | 43.9 | <0.0001 |
Established, months | 65.0 ± 64.4 | 65.3 ± 70.8 | 64.9 ± 62.7 | 0.49 | 67.2 ± 65.3 | 57.7 ± 60.9 | <0.001 |
Office SBP, mmHg | 159.3 ± 17.1 | 159.6 ± 17.9 | 159.3 ± 16.9 | 0.67 | 160.0 ± 17.4 | 157.6 ± 16.1 | <0.0001 |
Office DBP, mmHg | 93.5 ± 10.5 | 93.3 ± 10.8 | 93.5 ± 10.4 | 0.60 | 93.8 ± 10.6 | 92.7 ± 10.2 | <0.01 |
BP < 140/90 mmHg, % | 6.1 | 6.8 | 5.9 | 0.34 | 6.2 | 5.7 | 0.60 |
AZL-M treatment, % | 73.0 | 74.6 | 72.6 | 0.27 | 100.0 | 0.0 | |
ACE-inhibitor treatment, % | 27.0 | 25.4 | 27.4 | 0.27 | 0.0 | 100.0 | |
Comorbidity | |||||||
Diabetes, % | 19.3 | 17.5 | 19.8 | 0.15 | 19.4 | 19.3 | 0.96 |
Heart failure, % | 5.7 | 5.4 | 5.8 | 0.73 | 5.7 | 5.6 | 0.88 |
CAD, % | 9.6 | 8.9 | 9.8 | 0.44 | 8.9 | 11.5 | <0.05 |
Prior stroke/TIA, % | 2.8 | 3.7 | 2.5 | 0.09 | 2.8 | 2.5 | 0.59 |
PAD, % | 3.0 | 2.5 | 3.2 | 0.31 | 3.0 | 3.2 | 0.73 |
COPD, % | 7.4 | 3.6 | 8.2 | <0.0001 | 7.2 | 7.7 | 0.58 |
Renal function | |||||||
Known renal disease, % | 3.3 | 2.7 | 3.4 | 0.34 | 3.2 | 3.5 | 0.70 |
Microalbuminuria, % | 6.5 | 5.7 | 6.7 | 0.53 | 6.6 | 6.0 | 0.65 |